Keene & Associates Inc. Has $3.19 Million Position in Bristol-Myers Squibb (NYSE:BMY)

Keene & Associates Inc. boosted its position in Bristol-Myers Squibb (NYSE:BMY) by 2.1% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 61,555 shares of the biopharmaceutical company’s stock after purchasing an additional 1,242 shares during the quarter. Bristol-Myers Squibb comprises about 2.4% of Keene & Associates Inc.’s portfolio, making the stock its 22nd biggest holding. Keene & Associates Inc.’s holdings in Bristol-Myers Squibb were worth $3,185,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the company. Sunbelt Securities Inc. boosted its stake in shares of Bristol-Myers Squibb by 19.1% in the first quarter. Sunbelt Securities Inc. now owns 10,080 shares of the biopharmaceutical company’s stock valued at $547,000 after buying an additional 1,614 shares during the period. Brookstone Capital Management lifted its position in shares of Bristol-Myers Squibb by 36.4% during the 1st quarter. Brookstone Capital Management now owns 150,037 shares of the biopharmaceutical company’s stock valued at $8,137,000 after acquiring an additional 40,018 shares during the period. Future Financial Wealth Managment LLC acquired a new stake in shares of Bristol-Myers Squibb during the 1st quarter worth $83,000. Aspiriant LLC increased its position in shares of Bristol-Myers Squibb by 8.3% in the first quarter. Aspiriant LLC now owns 9,118 shares of the biopharmaceutical company’s stock worth $495,000 after purchasing an additional 702 shares during the period. Finally, Signet Financial Management LLC acquired a new position in Bristol-Myers Squibb in the first quarter valued at about $1,070,000. Institutional investors own 76.41% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have commented on the stock. Sanford C. Bernstein began coverage on shares of Bristol-Myers Squibb in a report on Thursday, October 17th. They issued a “market perform” rating and a $56.00 target price on the stock. Deutsche Bank Aktiengesellschaft decreased their price objective on shares of Bristol-Myers Squibb from $53.00 to $45.00 and set a “hold” rating on the stock in a research note on Tuesday, July 23rd. TD Cowen upped their target price on Bristol-Myers Squibb from $53.00 to $59.00 and gave the stock a “hold” rating in a research note on Monday, October 7th. Jefferies Financial Group raised their target price on Bristol-Myers Squibb from $49.00 to $51.00 and gave the company a “hold” rating in a report on Wednesday, August 28th. Finally, UBS Group boosted their price target on Bristol-Myers Squibb from $50.00 to $54.00 and gave the stock a “neutral” rating in a report on Wednesday, October 9th. Two analysts have rated the stock with a sell rating, fourteen have given a hold rating, one has assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $53.20.

Bristol-Myers Squibb Trading Up 0.6 %

BMY opened at $53.06 on Thursday. The company has a debt-to-equity ratio of 2.86, a current ratio of 1.16 and a quick ratio of 1.02. Bristol-Myers Squibb has a fifty-two week low of $39.35 and a fifty-two week high of $56.77. The company’s 50 day moving average price is $50.63 and its two-hundred day moving average price is $46.39. The firm has a market capitalization of $107.56 billion, a price-to-earnings ratio of -17.12, a PEG ratio of 13.75 and a beta of 0.46.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Friday, July 26th. The biopharmaceutical company reported $2.07 earnings per share for the quarter, topping the consensus estimate of $1.64 by $0.43. The company had revenue of $12.20 billion for the quarter, compared to analysts’ expectations of $11.54 billion. Bristol-Myers Squibb had a negative net margin of 14.06% and a positive return on equity of 12.51%. Bristol-Myers Squibb’s revenue for the quarter was up 8.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.75 earnings per share. As a group, research analysts predict that Bristol-Myers Squibb will post 0.77 earnings per share for the current year.

Bristol-Myers Squibb Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, November 1st. Stockholders of record on Friday, October 4th will be given a dividend of $0.60 per share. The ex-dividend date of this dividend is Friday, October 4th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 4.52%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is -77.42%.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.